Insmed Incorporated, a global biopharmaceutical company, recently presented significant findings from their respiratory portfolio at the American Thoracic Society 2025 International Conference. Among the highlights were the results from the Phase 3 ASPEN trial of brensocatib, which demonstrated consistent efficacy and safety in treating non-cystic fibrosis bronchiectasis (NCFBE) across three key patient subgroups. These subgroups included adolescents aged 12 and older, patients receiving macrolide therapy, and individuals with varying blood eosinophil levels. The trial showed brensocatib's ability to reduce pulmonary exacerbations, delay the time to the first exacerbation, and slow lung function decline compared to a placebo, with a safety profile comparable to the overall trial population. Additionally, Insmed shared data from a post-hoc analysis on lung function and health economics, as well as insights from their expanded Phase 2 analysis of treprostinil palmitil inhalation powder in patients with pulmonary hypertension linked to interstitial lung disease. These findings underscore Insmed's commitment to advancing research and developing therapies for serious respiratory diseases.